Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

Waters Corporation announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides pathologists and...

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, announced its telehealth prescribing program. This program connects eligible...

Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

Roche announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the cobas® eplex respiratory pathogen panel 3 (RP3). Designed for the automated cobas® eplex system, this flexible syndromic test offers up to five customizable panel...

SEKISUI Diagnostics Announces 510(k) Clearance and Launches the OSOM® COVID-19/Flu A&B Combo Test

SEKISUI Diagnostics, a global medical diagnostics manufacturer, has announced the launch of a 510(k) cleared rapid test to detect COVID-19 and Flu A&B in professional healthcare settings. The OSOM® COVID-19/Flu A&B Combo Test is a lateral flow...

Cresilon launched next-generation TRAUMAGEL.

Cresilon Inc. a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced the launch of TRAUMAGEL®'s next generation, which officially debuts at EMS World Expo 2026 in Orlando, Florida. This next generation...

Chemify Becomes the First Chemistry Hyperscaler with £22 Million in Grants from Scottish Enterprise and the UK Government

Chemify, the deep-tech pioneer of Chemputation, an end-to-end approach combining AI with robotic synthesis for molecular and materials discovery, has received £22 million ($29.7 million) in grants from Scottish Enterprise and the UK Government....

FDA Clears Roche's cobas® BV/CV Assay, Enabling Fast and Highly Accurate Diagnosis of Vaginitis

Roche announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay. This molecular diagnostic test provides results for both Bacterial vaginosis (BV) and...

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Merck, a leading global science and technology company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with...

Organon to Present New Analysis of VTAMA® (tapinarof) Cream, 1%

Organon a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced that a new analysis of Phase 3 data evaluating VTAMA cream. The presentation includes a pooled post hoc analysis...

Ori Biotech and ImmuXell Announce Strategic Partnership and First Patient Dosed

Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, and ImmuXell Biotech, a Shanghai-based clinical-stage cell therapy company, announced their strategic partnership which began in December 2025. The milestone: the first...

Presentations Highlight Results on LEROCHOL® (lerodalcibep-liga) Announced by LIB Therapeutics

LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small-dose, third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), announced results from two oral and two poster...

Digi-Tech Pharma & AI Conference 2026

The 9th Annual Digi-Tech Pharma & AI conference, a premier Pharmaceutical Technology Conference, brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare...

Hologic to Present New Data Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

Hologic, Inc. and its subsidiary, Biotheranostics, Inc., announced new data demonstrating how the Breast Cancer Index® (BCI™) Test results influence extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive...

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

Galvanize Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, today announced that it received U.S. Food and Drug Administration 510(k) clearance...

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

Ferring Pharmaceuticals announced a new real-world case series demonstrating that re-induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in approximately 31% (4/13) of patients with high-risk Bacillus...

BioOra Limited and Wellington Zhaotai Therapies Limited (WZTL) Execute Heads of Terms to Accelerate Global Expansion of CAR T-Cell Therapy

BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, announced the signing of a binding Heads of Terms agreement with Wellingto. Zhaotai Therapies Limited (Wellington Zhaotai) under which...

Merck’s once-daily IDVYNSO™ (doravirine/islatravir) receives FDA approval

Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1...

ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

ARUP Laboratories, a leader in diagnostic medicine and the largest nonprofit reference laboratory in the U.S., announced the launch of a new Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other...

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announced that the U.S. Food and Drug Administration (FDA) and European Commission have granted Orphan Drug...

New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday

Celltrion, Inc. announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis...

Results 1 - 20 of 57